Navigation Links
Iomai Stockholders Approve Merger With Intercell Subsidiary
Date:8/1/2008

GAITHERSBURG, Md., Aug. 1 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) announced today that its stockholders approved the merger of Iomai with a wholly-owned subsidiary of Intercell AG. Approximately 71.6 percent of Iomai's outstanding shares entitled to vote at the special meeting approved the merger, representing approximately 99.9 percent of the votes cast. The transaction remains subject to certain closing conditions. Assuming satisfaction of the remaining conditions, the transaction is anticipated to be completed on or about Aug. 5, 2008.

ABOUT IOMAI CORPORATION

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.


'/>"/>
SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
2. Iomai Announces Year-End 2007 Financial Results and Business Progress
3. Iomai to Announce Fourth Quarter and Year-End 2007 Financial Results and Host Webcast on Thursday, March 6
4. Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12
5. Iomai to Announce Third Quarter 2007 Financial Results and Host Webcast on Tuesday, November 13
6. Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers Diarrhea Patch at Keystone Conference
7. Iomai CEO to Speak at Natixis Bleichroeder Hidden Gems Conference on Monday
8. Milestone Scientific to Host 2008 Annual Meeting of Stockholders on Thursday, June 5, 2008 in New York City
9. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
10. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
11. Edwards Lifesciences to Webcast Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... Cambridge ... a splash at this year’s Bio-IT World Conference and Expo in Boston ... Data Lake® 4.0 solution. The Anzo Smart Data Lake is also a finalist ...
(Date:5/22/2017)... ... 2017 , ... Stratevi, a boutique firm that partners with healthcare companies to ... an office in downtown Boston at 745 Atlantic Ave. , “We are seeing ... evidence on the value they provide, not just to patients, but also payers. Having ...
(Date:5/22/2017)... ... May 22, 2017 , ... Cancer diagnostics and pathology ... B2 at the Association for Pathology Informatics Annual Summit at the ... demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, Inspirata will present research it ...
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose is a genetically ... error process by finding the right antidepressant faster. CNSDose speeds recovery and ... through a personalized approach to treatment. , A peer-reviewed and published, ...
Breaking Biology Technology:
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
Breaking Biology News(10 mins):